Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin and Serplulimab Maintenance in ES-SCLC
NCT06497530Phase 2Recruiting
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in small cell lung cancer (SCLC), sponsored by Guangzhou Institute of Respiratory Health. Started Dec 2024; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06497530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497530.